Insulet Corporation (PODD) fundamentals: P/E, valuation, undervalued?
Insulet Corporation · Health Care · ref. ETF XLV · price $138.13
In short — Insulet Corporation trades at 26.2× earnings (P/E), 17.9× forward, with a net margin of 12.3 % and revenue growth of +24 %. Read: Cheap for the growth (P/E 18 for ~329% growth (PEG 0.1)).
Is Insulet Corporation stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$138.13-56.6% over range
Oct 14, 25low $130.47 · high $346.36Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
50% recommend buying · 20 analysts
Valuation : Cheap for the growth — P/E 18 for ~329% growth (PEG 0.1)
Valuation
26.2
P/E (price/earnings)
17.9
Forward P/E
0.08
PEG
6.7
Price/book (P/B)
$9.6B
Market cap
5.28
EPS
Profitability & growth
12.3 %
Net margin
+24 %
Revenue growth
+329 %
Earnings growth
$948M
Total debt
Insulet Corporation income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $1.3B | $5M | 0.4 % |
| 2023 | $1.7B | $206M | 12.2 % |
| 2024 | $2.1B | $418M | 20.2 % |
| 2025 | $2.7B | $247M | 9.1 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Insulet Corporation's P/E and is the stock undervalued? What's a good P/E?
Insulet Corporation's P/E is 26.2 (forward 17.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Insulet Corporation profitable?
Insulet Corporation has a net margin of 12.3 % (EPS 5.28). The company is profitable.
Is PODD stock expensive?
Our read: "Cheap for the growth" — P/E 18 for ~329% growth (PEG 0.1). Cross-check with growth and sector.
💬 A question about Insulet Corporation? The JPI assistant answers using our backtest data.